Charles River Laboratories International Inc

Charles River Laboratories International Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)233.01
  • Today's Change6.54 / 2.89%
  • Shares traded375.07k
  • 1 Year change-42.86%
  • Beta1.2916
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions (Biologics), and Avian Vaccine Services (Avian).

  • Revenue in USD (TTM)3.69bn
  • Net income in USD443.35m
  • Incorporated1994
  • Employees18.60k
  • Location
    Charles River Laboratories International Inc251 Ballardvale StWILMINGTON 01887United StatesUSA
  • Phone+1 (781) 222-6000
  • Fax+1 (978) 988-5665
  • Websitehttps://www.criver.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CRL:NYQ since
Explora Biolabs Holdings IncDeal completed06 Apr 202206 Apr 2022Deal completed-19.28%295.00m
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Legend Biotech Corp116.94m-346.40m7.90bn1.07k--17.19--68.08-2.34-2.340.79562.840.1413--4.64109,184.90-41.84---53.94-------296.23--3.81--0.2276--18.65---27.26------
Organon & Co6.36bn1.11bn7.98bn9.30k7.25--,333.3010.29--13.71--63.16--17.42--
Novocure Ltd545.23m-68.24m8.04bn1.17k--18.81--15.35-0.6553-0.65535.244.250.48264.135.80467,208.20-6.04-7.62-6.80-8.8978.7075.32-12.52-12.027.87-6.660.5608--8.2345.20-783.35--6.47--
Elanco Animal Health Inc4.65bn-175.00m9.07bn9.00k--1.3017.941.99-0.3599-0.35999.5015.060.28651.444.69516,222.20-1.08-2.15-1.20-2.3856.8051.14-3.77-7.161.471.740.4592--45.5710.3415.73--12.30--
Jazz Pharmaceuticals PLC3.48bn-51.87m9.81bn3.20k--3.0815.682.83-0.864-0.86455.8951.110.28520.4936.331,087,952.00-0.31973.94-0.34194.2485.0491.47-1.1210.962.451.300.65290.0030.9115.77-238.16---24.32--
United Therapeutics Corporation1.79bn630.80m9.98bn965.0016.782.3314.805.6413.2013.2037.4094.930.34441.3110.321,853,575.0012.1410.5812.9511.7393.4191.8135.2724.627.8313.250.15630.0013.631.06-7.58-7.7922.83--
Neurocrine Biosciences, Inc.1.30bn12.20m10.30bn900.00897.247.17405.297.880.1190.11913.4514.890.65460.61465.931,440,889.000.61586.800.70458.1998.6498.940.940811.523.47--0.1061--8.38137.50-78.00--41.62--
Charles River Laboratories Intl. Inc3.69bn443.35m10.91bn18.60k26.294.3515.603.128.628.6271.6952.060.517610.245.30198,282.106.336.617.407.8537.3637.1512.2310.931.0816.940.52690.0021.0816.067.3220.4132.85--
Viatris Inc17.19bn760.80m12.68bn37.00k17.210.65933.280.75990.62580.625814.1716.340.3152.474.87464,505.401.39-0.36851.67-0.442841.8138.974.43-1.170.98474.780.5145--49.7310.06-89.45---7.46--
Repligen Corporation778.77m159.43m13.59bn1.85k92.457.8769.5618.262.772.7713.5032.550.34921.746.96420,502.207.153.998.614.5258.1256.8520.4714.921.7436.320.1358--83.0845.02114.0861.4975.14--
Data as of Aug 12 2022. Currency figures normalised to Charles River Laboratories International Inc's reporting currency: US Dollar USD

Institutional shareholders

40.20%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20225.73m11.29%
BlackRock Fund Advisorsas of 31 Mar 20223.18m6.27%
Fidelity Management & Research Co. LLCas of 31 Mar 20222.22m4.37%
SSgA Funds Management, Inc.as of 31 Mar 20222.02m3.98%
Kayne Anderson Rudnick Investment Management LLCas of 31 Mar 20221.64m3.23%
ClearBridge Investments LLCas of 31 Mar 20221.37m2.70%
Massachusetts Financial Services Co.as of 31 Mar 20221.14m2.25%
BlackRock Advisors LLCas of 31 Mar 20221.11m2.19%
William Blair Investment Management LLCas of 31 Mar 20221.05m2.06%
Geode Capital Management LLCas of 31 Mar 2022958.62k1.89%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.